Tumor Identification of Less Aggressive or Indolent Lymphoma With Whole-Body 11C-Acetate PET/CT

Abstract

Purpose The aim of this study was to investigate the diagnostic performance of whole-body [11C]acetate PET/CT in less aggressive or indolent lymphomas, wherein [18F]FDG PET/CT would exhibit limited sensitivity. Methods Between September 2016 and May 2018, we prospectively evaluated 17 patients (9 men, 8 women; mean age [range], 71 [45–87] years) with pathologically proven less aggressive or indolent lymphomas according to Non-Hodgkin's Lymphoma Classification Project, using both [18F]FDG PET/CT and [11C]acetate PET/CT (performed on the same day). Detected nodal lesions were recorded according to the Ann Arbor classification. Extranodal (EN) lesions were also evaluated. We compared whole-body lesion detection between [18F] FDG PET/CT and [11C]acetate PET/CT using the McNemar test. Results In all patients, significantly more nodal and EN lesions were detected using [11C]acetate PET/CT than [18F]FDG PET/CT (nodal: 84 vs 64 regions; P < 0.001; EN: 26 vs 19 regions, P = 0.039). Bone lesions were detected in 8 and 5 patients using [11C]acetate PET/CT and [18F]FDG PET/CT, respectively (P = 0.25). Among the 14 patients (82.4%) who underwent bone marrow biopsy, bone marrow involvement was detected with sensitivities of 100% (6/6 patients) and 80% (5/6 patients) using [11C]acetate PET/CT and [18F]FDG PET/CT, respectively. Multiple areas of focal uptake in the spleen of 1 patient were exhibited on [18F]FDG PET/CT but not [11C]acetate PET/CT. Conclusions [11C]acetate PET/CT exhibited greater sensitivity than [18F]FDG PET/CT for lesion detection in patients with less aggressive or indolent lymphomas, thus promising applicability as a physiological tracer in the study of such lesions.

Workload of diagnostic radiologists in the foreseeable future based on recent scientific advances: growth expectations and role of artificial intelligence

“…All other studies were considered to have an unclear impact on workload. Study examples are shown in Tables 2 and 3 [16][17][18][19][20][21][22][23][24][25][26].…”

FDG PET/CT versus Bone Marrow Biopsy for Diagnosis of Bone Marrow Involvement in Non-Hodgkin Lymphoma: A Systematic Review

“…For the mixed population of indolent NHL the results of this review indicated that BMB is far more sensitive in indolent NHL than [ 18 F]FDG PET/CT and thus it is not recommended to replace the routine BMB with PET/CT for identifying BMI in such patients, as many cases will be missed. For less aggressive or indolent lymphomas 11C-Acetate PET/CT might be a promising approach although it requires further evaluation as it has been found to achieve a higher sensitivity compared to the [ 18 F]FDG PET/CT [58]. The largest percentage (about 70%) of all indolent lymphomas worldwide are FL [59].…”

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

“…PET‐CT is of great value in assessment of tumor burden and treatment efficacy 30 . To evaluate the role of metabolic activity of lymphoma on CAR‐T therapy, we analyzed the correlation of SUVmax, and we also evaluated the correlation of TLG, which was determined by SUVmean and TMV.…”